Document is current
Any future updates will be listed below
-
Authors
Rotta, Giulia https://orcid.org/0000-0001-6897-9225
Gilardoni, Ettore
Ravazza, Domenico
Mock, Jacqueline
Seehusen, Frauke
Elsayed, Abdullah https://orcid.org/0000-0001-7080-0853
Puca, Emanuele
De Luca, Roberto
Pellegrino, Christian https://orcid.org/0000-0001-7898-9988
Look, Thomas
Weiss, Tobias https://orcid.org/0000-0002-5533-9429
Manz, Markus G https://orcid.org/0000-0002-4676-7931
Halin, Cornelia https://orcid.org/0000-0002-7899-2850
Neri, Dario https://orcid.org/0000-0001-5234-7370
Dakhel Plaza, Sheila https://orcid.org/0000-0003-2546-6053
- License Information
-
More Information
Article History
Received: 24 October 2023
Revised: 29 January 2024
Accepted: 30 January 2024
First Online: 6 March 2024
Disclosure and competing interests statement
: DN is a co-founder and shareholder of Philogen S.p.A. ( ), a Swiss-Italian Biotech company that operates in the field of ligand-based pharmacodelivery. GR, EG, DR, JM, AE, EP, RDL, and SDP are employees of Philochem AG, a daughter company of Philogen, acting as the discovery unit of the group. CH is a member of the scientific advisory board of Philogen S.p.A. GR and SDP are inventors on a patent application (Patent number: WO2023131611 A1) filed by Philogen S.p.A covering the technology described in this work. The other authors declare that they have no competing interests.
